Melody A. Cobleigh, MD

Below is a list of scientific publications for which this practitioner was either the primary author or a contributor. Citations come from PubMed, a database of biomedical literature, life science journals and online books. PubMed is a service of the US Library of Medicine at the National Institutes of Health. Click on the title of the cited work for more information (this will take you directly to PubMed.gov). Listings go back five years.

1. Adjuvant endocrine therapy for breast cancer.
   Rao RD, Cobleigh MA.
   Oncology (Williston Park). 2012
   2012 Jun
   26(6):541-7, 550, 552 passim. Review.
   
2. Other options in the treatment of advanced breast cancer.
   Cobleigh MA.
   Semin Oncol.
   2011 Jun
   38 Suppl 2:S11-6
   
3. Impact of exploratory biomarkers on the treatment effect of bevacizumab in metastatic breast cancer
   Jubb AM, Miller KD, Rugo HS, Harris AL, Chen D, Reimann JD, Cobleigh MA, Schmidt M, Langmuir VK, Hillan KJ, Chen DS, Koeppen H
   Clin Cancer Res
   2011 Jan 15
   17(2):372-81
   
4. Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs. tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group
   Rao RD, Cobleigh MA, Gray R, Graham ML 2nd, Norton L, Martino S, Budd GT, Ingle JN, Wood WC
   Med Oncol
   2010 Sep 28
   
5. Efficacy and safety of erlotinib in patients with locally advanced or metastatic breast cancer
   Dickler MN, Cobleigh MA, Miller KD, Klein PM, Winer EP
   Breast Cancer Res Treat
   2009 May
   115(1):115-21
   
6. ACR appropriateness criteria on postmastectomy radiotherapy expert panel on radiation oncology-breast
   Taylor ME, Haffty BG, Rabinovitch R, Arthur DW, Halberg FE, Strom EA, White JR, Cobleigh MA, Edge SB
   Int J Radiat Oncol Biol Phys
   2009 Mar 15
   73(4):997-1002
   
7. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
   Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD; ECOG 2100
   J Clin Oncol
   2008 Oct 1
   26(28):4672-8
   
8. Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane
   Burstein HJ, Elias AD, Rugo HS, Cobleigh MA, Wolff AC, Eisenberg PD, Lehman M, Adams BJ, Bello CL, DePrimo SE, Baum CM, Miller KD
   J Clin Oncol
   2008 Apr 10
   26(11):1810-6
   

• To watch a brief video of Melody A. Cobleigh, MD, click the play button at the lower left corner of the video frame below.
• (If you cannot play the video, you may need to update to the latest version of Adobe Flash Player.)
• View Transcript

• We were part of the original group of investigators looking at a new treatment for breast cancer called Herceptin. And we were dealing with some patients who were extremely ill who got better right before our eyes. And that was one of the most rewarding experiences of my life in medicine. That medication was approved about 10 years ago, and now it’s part of the standard of care for breast cancer. And Rush was right in on the ground floor. It’s pretty neat to be taking a chance on a new treatment strategy not involving chemotherapy, surgery or radiation. We like the idea of using the patient’s own immune system to help fight her cancer, and we watch tumors basically melt away over a period of a week or two.